BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 16447221)

  • 21. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
    Polzer K; Neubert K; Meister S; Frey B; Baum W; Distler JH; Gückel E; Schett G; Voll RE; Zwerina J
    Arthritis Rheum; 2011 Mar; 63(3):670-80. PubMed ID: 21360496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vitamin D receptor regulates TNF-mediated arthritis.
    Zwerina K; Baum W; Axmann R; Heiland GR; Distler JH; Smolen J; Hayer S; Zwerina J; Schett G
    Ann Rheum Dis; 2011 Jun; 70(6):1122-9. PubMed ID: 21415051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteoclasts are essential for TNF-alpha-mediated joint destruction.
    Redlich K; Hayer S; Ricci R; David JP; Tohidast-Akrad M; Kollias G; Steiner G; Smolen JS; Wagner EF; Schett G
    J Clin Invest; 2002 Nov; 110(10):1419-27. PubMed ID: 12438440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.
    Zhang Q; Badell IR; Schwarz EM; Boulukos KE; Yao Z; Boyce BF; Xing L
    Arthritis Rheum; 2005 Sep; 52(9):2708-18. PubMed ID: 16142752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone and joint destruction in rheumatoid arthritis: what is really happening?
    Goldring SR
    J Rheumatol Suppl; 2002 Sep; 65():44-8. PubMed ID: 12236623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory T cells protect from local and systemic bone destruction in arthritis.
    Zaiss MM; Frey B; Hess A; Zwerina J; Luther J; Nimmerjahn F; Engelke K; Kollias G; Hünig T; Schett G; David JP
    J Immunol; 2010 Jun; 184(12):7238-46. PubMed ID: 20483756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis.
    Koenders MI; Marijnissen RJ; Devesa I; Lubberts E; Joosten LA; Roth J; van Lent PL; van de Loo FA; van den Berg WB
    Arthritis Rheum; 2011 Aug; 63(8):2329-39. PubMed ID: 21520013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis.
    Blüml S; Binder NB; Niederreiter B; Polzer K; Hayer S; Tauber S; Schett G; Scheinecker C; Kollias G; Selzer E; Bilban M; Smolen JS; Superti-Furga G; Redlich K
    Arthritis Rheum; 2010 Jun; 62(6):1608-19. PubMed ID: 20155834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase.
    Chopra P; Kulkarni O; Gupta S; Bajpai M; Kanoje V; Banerjee M; Bansal V; Visaga S; Chatterjee M; Chaira T; Shirumalla RK; Verma AK; Dastidar SG; Sharma G; Ray A
    Int Immunopharmacol; 2010 Apr; 10(4):467-73. PubMed ID: 20093202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
    Schett G; Redlich K; Hayer S; Zwerina J; Bolon B; Dunstan C; Görtz B; Schulz A; Bergmeister H; Kollias G; Steiner G; Smolen JS
    Arthritis Rheum; 2003 Jul; 48(7):2042-51. PubMed ID: 12847699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice.
    Van Lent PL; Van De Loo FA; Holthuysen AE; Van Den Bersselaar LA; Vermeer H; Van Den Berg WB
    J Rheumatol; 1995 Dec; 22(12):2250-8. PubMed ID: 8835558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
    Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
    J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of arthritic bone destruction by adenovirus-mediated dominant-negative Ras gene transfer to synoviocytes and osteoclasts.
    Yamamoto A; Fukuda A; Seto H; Miyazaki T; Kadono Y; Sawada Y; Nakamura I; Katagiri H; Asano T; Tanaka Y; Oda H; Nakamura K; Tanaka S
    Arthritis Rheum; 2003 Sep; 48(9):2682-92. PubMed ID: 13130489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis.
    Korb-Pap A; Stratis A; Mühlenberg K; Niederreiter B; Hayer S; Echtermeyer F; Stange R; Zwerina J; Pap T; Pavenstädt H; Schett G; Smolen JS; Redlich K
    Ann Rheum Dis; 2012 Jun; 71(6):1004-11. PubMed ID: 22258493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD44 is a determinant of inflammatory bone loss.
    Hayer S; Steiner G; Görtz B; Reiter E; Tohidast-Akrad M; Amling M; Hoffmann O; Redlich K; Zwerina J; Skriner K; Hilberg F; Wagner EF; Smolen JS; Schett G
    J Exp Med; 2005 Mar; 201(6):903-14. PubMed ID: 15781582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p38 MAPK as a potential therapeutic target for inflammatory osteolysis.
    Wei S; Siegal GP
    Adv Anat Pathol; 2007 Jan; 14(1):42-5. PubMed ID: 17198310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis.
    Schett G; Stolina M; Dwyer D; Zack D; Uderhardt S; Krönke G; Kostenuik P; Feige U
    Arthritis Rheum; 2009 Sep; 60(9):2644-54. PubMed ID: 19714640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice.
    Schurigt U; Hummel KM; Petrow PK; Gajda M; Stöckigt R; Middel P; Zwerina J; Janik T; Bernhardt R; Schüler S; Scharnweber D; Beckmann F; Saftig P; Kollias G; Schett G; Wiederanders B; Bräuer R
    Arthritis Rheum; 2008 Feb; 58(2):422-34. PubMed ID: 18240253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenesis of Lyme neuroborreliosis: mitogen-activated protein kinases Erk1, Erk2, and p38 in the response of astrocytes to Borrelia burgdorferi lipoproteins.
    Ramesh G; Philipp MT
    Neurosci Lett; 2005 Aug 12-19; 384(1-2):112-6. PubMed ID: 15893422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cartilage-specific constitutive expression of TSG-6 protein (product of tumor necrosis factor alpha-stimulated gene 6) provides a chondroprotective, but not antiinflammatory, effect in antigen-induced arthritis.
    Glant TT; Kamath RV; Bárdos T; Gál I; Szántó S; Murad YM; Sandy JD; Mort JS; Roughley PJ; Mikecz K
    Arthritis Rheum; 2002 Aug; 46(8):2207-18. PubMed ID: 12209527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.